Literature DB >> 11849412

Molecular and structural consequences of early renal allograft injury.

Keshwar Baboolal1, Geraint A Jones, Alenka Janezic, David R Griffiths, Wieslaw A Jurewicz.   

Abstract

BACKGROUND: Chronic allograft nephropathy is an important cause of graft failure. Many donor and recipient factors contribute to its development. Prospective analysis of these factors has been hindered by the lack of sensitive and specific indicators of renal injury. As a consequence protocol biopsies have been increasingly used in the assessment of renal allograft injury. We performed protocol renal allograft biopsies to prospectively examine the role of important determinants and mediators of chronic allograft nephropathy.
METHODS: A total of 51 consecutive cadaveric renal transplant recipients entered a randomized prospective study of tacrolimus (Tac) versus cyclosporine (CsA) microemulsion based immunosuppression. Study patients underwent protocol renal allograft biopsies at the time of engraftment and at 3, 6 and 12 months post-transplantation. Biopsies were analyzed by quantitative polymerase chain reaction (PCR) for mRNA for transforming growth factor-beta (TGF-beta), thrombospondin, and fibronectin. Measurements of renal structural injury were estimated by quantitative assessment of interstitial fibrosis and glomerulosclerosis. Changes in profibrotic growth factors and renal structural injury were related to donor and recipient determinants by stepwise regression analysis.
RESULTS: Longitudinal assessment of renal injury demonstrated an early and progressive increase in mRNA for TGF-beta, thrombospondin (TSP) and fibronectin (FBN): TGF-beta baseline, 1.9 +/- 0.2 log copies; TGF-beta 6 months, 2.5 +/- 0.2 log copies, P < 0.05 6 months vs. baseline; TSP baseline, 1.9 +/- 0.2 log copies; TSP 6 months, 2.4 +/- 0.2 log copies, P < 0.05 6 months vs. baseline; FBN baseline, 2.0 +/- 0.2 log copies; FBN 12 months, 2.3 +/- 0.2 log copies, P < 0.05 12 months vs. baseline. This increase in profibrotic growth factors within the allograft was associated with a significant increase in interstitial fibrosis (Vvi) on renal biopsies: Vvi baseline, 13 +/- 1%; Vvi 3 months, 18 +/- 1%; Vvi 6 months, 28 +/- 2%; Vvi 12 months, 34 +/- 2%; P < 0.05 3, 6, and 12 months vs. baseline. Histological analysis demonstrated chronic allograft nephropathy in 4% biopsies at 3 months, 12% at 6 months and in 49% at 12 months. These changes in renal structure were not associated with any change in creatinine clearance (CCr): CCr 3 months, 56 +/- 2 mL/min, CCr 24 months, 56 +/- 2 mL/min; P=NS. Stepwise regression analysis of key donor and recipient determinants of chronic renal injury identified calcineurin inhibitors and acute rejection episodes as important factors involved in the development of chronic renal injury. In particular, the use of cyclosporine compared to tacrolimus was associated with a tenfold increase in TGF-beta mRNA (TGF-beta mRNA at 6 months, CsA vs. Tac, 3 +/- 0.3 vs. 2 +/- 0.3 log copies, P < 0.05), interstitial fibrosis (Vvi at 6 months, CsA vs. Tac, 33 +/- 4% vs. 24 +/- 2%, P < 0.05). Changes in growth factors and renal structure predicted impaired renal function (CCr at 12 months, CsA vs. Tac, 53 +/- 4 mL/min vs. 62 +/- 2 mL/min, P < 0.05). Similarly, acute rejection episodes were associated with an accelerated development of interstitial fibrosis (Vvi at 6 months, acute rejection vs. no rejection, 34 +/- 3% vs. 25 +/- 2%; P < 0.05), but not with changes in TGF-beta, thrombospondin or fibronectin expression.
CONCLUSION: Our results suggest that structural injury develops early in the natural history of the renal allograft and is mediated, in part, by the early up-regulation of profibrotic growth factors. We have determined that calcineurin inhibitors, in particular cyclosporine, and acute rejection episodes are key factors in the development of renal structural injury.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11849412     DOI: 10.1046/j.1523-1755.2002.00149.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  19 in total

1.  The time interval between kidney and pancreas transplantation and the clinical outcomes of pancreas after kidney transplantation.

Authors:  Fu L Luan; Mallika Kommareddi; Diane M Cibrik; Millie Samaniego; Akinlolu O Ojo
Journal:  Clin Transplant       Date:  2011-10-17       Impact factor: 2.863

2.  Laser-assisted microdissection of the kidney: fundamentals and applications.

Authors:  Gregory L Blakey; Zoltan G Laszik
Journal:  J Mol Histol       Date:  2004-08       Impact factor: 2.611

3.  Protocol biopsies should not (yet) be the standard of care in pediatric renal transplant recipients.

Authors:  Ron Shapiro; Thomas E Starzl
Journal:  Pediatr Transplant       Date:  2006-11

4.  Urinary expression of kidney injury markers in renal transplant recipients.

Authors:  Cheuk-Chun Szeto; Bonnie Ching-Ha Kwan; Ka-Bik Lai; Fernand Mac-Moune Lai; Kai-Ming Chow; Gang Wang; Cathy Choi-Wan Luk; Philip Kam-Tao Li
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-29       Impact factor: 8.237

5.  Inflammatory macrophage-associated 3-gene signature predicts subclinical allograft injury and graft survival.

Authors:  Tej D Azad; Michele Donato; Line Heylen; Andrew B Liu; Shai S Shen-Orr; Timothy E Sweeney; Jonathan Scott Maltzman; Maarten Naesens; Purvesh Khatri
Journal:  JCI Insight       Date:  2018-01-25

6.  Comparable Renal Function at 6 Months with Tacrolimus Combined with Fixed-Dose Sirolimus or MMF: Results of a Randomized Multicenter Trial in Renal Transplantation.

Authors:  Eveline Van Gurp; Jesus Bustamante; Antonio Franco; Lionel Rostaing; Thomas Becker; Eric Rondeau; Zenon Czajkowski; Andrzej Rydzewski; Antonio Alarcon; Petr Bachleda; Jiri Samlik; Dirk Burmeister; Luis Pallardo; Marie-Christine Moal; Boleslaw Rutkowski; Zbigniew Wlodarczyk
Journal:  J Transplant       Date:  2010-10-05

7.  Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study.

Authors:  Philip J O'Connell; Weijia Zhang; Madhav C Menon; Zhengzi Yi; Bernd Schröppel; Lorenzo Gallon; Yi Luan; Ivy A Rosales; Yongchao Ge; Bojan Losic; Caixia Xi; Christopher Woytovich; Karen L Keung; Chengguo Wei; Ilana Greene; Jessica Overbey; Emilia Bagiella; Nader Najafian; Milagros Samaniego; Arjang Djamali; Stephen I Alexander; Brian J Nankivell; Jeremy R Chapman; Rex Neal Smith; Robert Colvin; Barbara Murphy
Journal:  Lancet       Date:  2016-07-22       Impact factor: 79.321

Review 8.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  [Current problems of kidney transplantation].

Authors:  H Haller; N Richter; V Bröcker; W Gwinner; F Gueler; A Schwarz
Journal:  Internist (Berl)       Date:  2009-05       Impact factor: 0.743

10.  Evaluation of gene panel mRNAs in urine samples of kidney transplant recipients as a non-invasive tool of graft function.

Authors:  Valeria R Mas; Luciana A Mas; Kellie J Archer; Kenneth Yanek; Anne L King; Eric M Gibney; Adrian Cotterell; Robert A Fisher; Marc Posner; Daniel G Maluf
Journal:  Mol Med       Date:  2007 May-Jun       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.